Novoste is out to show that the changing device world still has room, in the right market, for a small single-product company to succeed against larger competitors.

The recent consolidations among national hospital groups has left many suppliers feeling a significant loss of leverage in contract negotiations. But what hospitals don't realize is that consolidation on the supplier side, due to market attrition and increased merger and acquisitions, has created suppliers nearly invulnerable to competitive pressure. As the number of players on both sides of the table shrinks, has consolidation in hospital supply gone too far?

This articles reviews 1994's intense merger activity. The big hospital and home infusion mergers have created enormous national organizations, but the rise of locally powerful integrated systems undercuts their clout. Consolidation in the device industry reflects the devaluation of incremental technological improvements and providers' needs to cut their list of separate suppliers. Diagnostics gained new players as biotechs, which believe they can successfully mix diagnostic and therapeutic product marketing efforts, bought into the business. Drug firms were energetic acquirors, but few of their deals were copycat transactions. Most were driven by very different motivations, including the idea of acquiring the capability to cover an entire episode of care, not merely the drug used.